Acurx Pharmaceuticals

Historical price data

Acurx Pharmaceuticals is a publicly traded, clinical-stage biotech focused on developing DNA polymerase IIIC inhibitors, a new class of antibiotics for Gram-positive bacterial infections deemed urgent threats. Its primary achievement is advancing its lead candidate, ibezapolstat, into a Phase 2b trial for CDI, with promising early clinical data. The company's strategy is to leverage its focused platform and experienced leadership to achieve regulatory approval for ibezapolstat, potentially under expedited pathways, while exploring the broader utility of its mechanism against other resistant pathogens like MRSA and VRE.

Acurx's platform is based on a novel class of small molecule antibiotics that inhibit the bacterial enzyme DNA polymerase IIIC (pol IIIC), a target essential for DNA replication in Gram-positive bacteria but absent in human cells.

In CDI, ibezapolstat competes with generic vancomycin, branded fidaxomicin, and microbiome-based therapies. Its potential differentiation lies in its novel mechanism and microbiome-sparing profile. In the broader Gram-positive space, its preclinical candidate ACX-375C would enter a crowded field years behind established and late-stage competitors.